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Abstract
Objectives: To determine whether for a given waist circumference (WC), a larger hip circumference (HC) was associated with
a reduced risk of insulin resistance, type 2 diabetes (T2D), hypertension and cardiovascular disease (CVD) in HIV-infected
patients. A second objective was to determine whether, for a given WC, the addition of HC improved upon estimates of
abdominal adiposity, in particular visceral adipose tissue (VAT), compared to those obtained by WC alone.
Methods: HIV-infected men (N= 1481) and women (N= 841) were recruited between 2005 and 2009. WC and HC were
obtained using standard techniques and abdominal adiposity was measured using computed tomography.
Results: After control for WC and covariates, HC was negatively associated with risk of insulin resistance (p,0.05) and T2D
[Men: OR= 0.91 (95% CI: 0.86–0.96); Women: OR= 0.91 (95% CI: 0.84–0.98)]. For a given WC, HC was also negatively
associated with a lower risk of hypertension (p,0.05) and CVD [OR = 0.94 (95% CI: 0.88–0.99)] in men, but not women.
Although HC was negatively associated with VAT in men and women after control for WC (p,0.05), the addition of HC did
not substantially improve upon the prediction of VAT compared to WC alone.
Conclusions: The identification of HIV-infected individuals at increased health risk by WC alone is substantially improved by
the addition of HC. Estimates of visceral adipose tissue by WC are not substantially improved by the addition of HC and thus
variation in visceral adiposity may not be the conduit by which HC identifies increased health risk.
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Introduction
Waist (WC) and hip circumference (HC) have independent and
opposite associations with type 2 diabetes (T2D) [1,2,3,4,5,6,7]
and cardiovascular disease (CVD) [4,6,8,9,10,11,12,13] in the
general population. For a given WC, an increase in HC is
associated with a reduction in health risk, whereas for a given HC
a larger WC is associated with an increase in health risk. More
importantly, it appears that the combination of WC and HC
identify adults at increased risk for morbidity and mortality better
than either alone [7,9,10,13,14,15,16]. Whether the combination
of WC and HC can improve upon the identification of HIV-
infected patients at increased health risk compared to WC alone is
unknown.
Mechanisms that explain why HC is negatively associated with
increased cardiometabolic risk for a given WC are unclear. One of
the emerging mechanisms suggests that the increase in morbidity
associated with a lower HC for a given WC may be explained by
the presence of dysfunctional, insulin-resistant peripheral subcu-
taneous adipocytes [17]. This could lead to impaired storage of
excess energy and thus a reduction in adipose tissue mass reflected
by a smaller HC or thigh circumference (ThC). Accordingly lower-
body subcutaneous adipose tissue may act as a buffer by storing
excess energy thus avoiding lipid spillover into ectopic tissues, such
as visceral adipose tissue (VAT) [17]. Indeed, we have previously
reported that HC is negatively associated with VAT after control
for WC in non-HIV individuals [18]. Confirmation in HIV-
infected patients treated with antiretroviral therapy (ART), a
known component of adipocyte dysfunction [19], would provide at
least one mechanism by which a reduction in HC for a given WC
is associated with an increase in health risk.
Based on these observations we reasoned that the combination
of WC and HC or ThC may provide an improved, pragmatic
approach for identifying HIV-infected patients at increased health
risk. Given the established association between VAT and
morbidity in HIV-infected individuals, we also determined
whether for a given WC, the addition of HC or ThC improved
upon estimates of VAT compared to those obtained by WC alone.
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Methods
Subjects
Participants included 2322 HIV-infected patients (1481 men
and 841 women) recruited at the metabolic clinic of the University
of Modena and Reggio Emilia in Italy between 2005 and 2009.
Patients from HIV clinics throughout Italy are referred or have
direct access to the multidisciplinary treatment at the metabolic
clinic where they obtain comprehensive metabolic and anthropo-
metric diagnostic and therapeutic assessments for the presence of
lipodystrophy and non-infectious comorbidities.
Inclusion criteria were serologically documented HIV-1 infec-
tion, age .18 years and at least 18 months of ART exposure. A
signed informed-consent form to participate in this study was
obtained from each patient. The study was approved by the local
institutional review board (Comitato Etico Provinciale di Mod-
ena).
Demographics
Demographic and clinical data, including duration of HIV
infection, ART history, and lifestyle were obtained by medical
chart review. Smoking was separated as follows: non-smoker (,1
cigarettes per day) or smoker ($1 cigarettes per day). Alcohol
consumption was separated into no alcohol (,10 g of ethanol per
day) or alcohol ($10 g of ethanol per day). Physical activity was
defined as mild or intense when ,4 or $4 hours per week of
exercise, respectively, were reported.
Anthropometric Measurements
All patients underwent physical examinations on the day fasting
blood was obtained. WC was measured at the narrowest point
mid-way between the lowest rib and the iliac crest at the end of
expiration with the subject standing. HC was taken at the largest
point at the level of the greater trochanters, and thigh
circumference was measured mid-way between the hip and knee.
All circumference measures were calculated as the average of three
measurements. BMI was calculated as weight in kilograms divided
by the square of height in meters.
Body Composition
A single CT image at the level of the L4 vertebra was taken for
quantification of VAT and abdominal subcutaneous adipose tissue
using a 64-multislice CT scanner (LightSpeed VTC; General
Electric Medical System). Each CT image was analyzed using
software application based on Advantage Windows 4.4 GE
medical system. Two radiologists assessed CT images for VAT
and abdominal subcutaneous adipose tissue. Agreement between
operators for VAT and abdominal subcutaneous adipose tissue
measurements was calculated on a subset of 40 scans and
demonstrated a high repeatability (r = 0.97, b=0.98 and r = 0.97
and b=1.01 respectively). The mean difference for VAT and
abdominal subcutaneous adipose tissue was 20.560.8 and
0.460.8 cm3 respectively.
Cardiometabolic Risk Factors
Total cholesterol, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, triglyceride, glucose, and insulin
levels were measured after an overnight fast. Insulin resistance was
calculated using the homeostasis model assessment equation
(HOMA-IR= [fasting insulin (mU/ml) 6 fasting glucose (mmol/
L)/22.5].
Criteria for Disease
A cut-point of HOMA-IR $3 was used to define insulin
resistance. T2D was diagnosed according to the American
Diabetes Association criteria, past medical history of diabetes or
use of glucose lowering therapy [20]. Hypertension was defined as
a systolic pressure $140 mmHg or a diastolic pressure
$90 mmHg. Cardiovascular events (CVD) were defined as
myocardial infarction, revascularization, stroke, and/or peripheral
vascular disease that occurring either before or after the clinical
evaluation within a 5-year period. This was chosen to increase the
statistical power of the sample size calculation.
Statistical Analyses
All statistical analyses were performed separately for men and
women due to gender interactions as well as the well-known
differences in body shape between men and women. Patient
characteristics were compared between men and women:
categorical variables were analyzed using Chi-squared test, while
continuous variables were compared using Student’s T-test or
Mann-Whitney test where appropriate. Events were coded as 0 (no
event) and 1 (event). Univariate and multivariate logistic regression
analyses were used to determine the associations between WC,
HC, ThC and BMI with HOMA-IR, T2D, hypertension and
CVD. Odds ratios (OR) with 95% confidence intervals (CI) are
expressed after adjustment for covariates. For all events, age,
smoking, and physical activity were included as covariates in the
analyses. Univariate and multivariate linear regressions were
performed to determine the independent associations between
WC, HC, ThC and BMI with total abdominal adipose tissue,
VAT and abdominal subcutaneous adipose tissue. All statistical
analyses were performed using STATA 12.1 Intercooled version
for Mac, StataCorp, College Station, TX, USA.
Results
Despite similarity in age (Men 45.967.3, Women 43.166.9)
and presenting with generally lower circumference values, the
women were characterized by greater subcutaneous adipose tissue
and less lean mass compared to men (Table 1). As expected men
had more VAT while women had more abdominal subcutaneous
adipose tissue. In general women presented with more favorable
lipid profiles compared to men. The prevalence rates were 44.8%
and 37.9% for HOMA-IR, 9.1% and 5.7% for T2D, 43.1% and
23.6% for hypertension and 5.1% and 1.6% for CVD in men and
women, respectively (Table 1). Sixty-two CVD events were
reported before and 27 events within two years after the clinical
evaluation. Women had a marginally longer exposure to ART
compared to men, while levels of CD4 did not differ between the
two groups.
Anthropometric Associations with HOMA-IR, T2D,
Hypertension and CVD
Univariate analyses revealed that WC was positively associated
with HOMA-IR, hypertension and CVD in men and women as
well as T2D in men (Table 2). HC was positively associated with
HOMA-IR and hypertension in men and women. With the
exception of HOMA-IR, thigh circumference alone was not
associated with any cardiometabolic risk factor or morbidity.
Multivariate associations between WC, HC, ThC and BMI with
HOMA-IR, T2D, hypertension and CVD are shown in Table 3.
Whereas for a given WC, HC attenuated the risk for cardiometa-
bolic risk factors and morbidity, for a given HC, WC increased the
risk. Indeed, for a given WC, a 1 cm greater HC was associated
with a 7–9% reduction in risk for HOMA-IR and T2D in men
Waist and Hip Circumference Identify Risk in HIV
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e62538
and women. Whereas for a given HC, a 1 cm greater WC was
associated with a 5–13% increase in risk for HOMA-IR and T2D
in men and women compared to a 3–8% increase in risk when
WC was used alone. In men, WC and HC also showed
independent and inverse associations with hypertension and
CVD (Table 3). For a given WC, a 1 cm larger HC was
associated with a 4–6% reduction in risk for hypertension and
CVD in men. Whereas, for a given HC, a 1 cm larger WC was
associated with a 5–6% increase in risk for hypertension, and
CVD in men compared to a 4% increase in risk when WC was
used alone.
With few exceptions, the addition of ThC or BMI to WC was
not associated with a reduction in risk for HOMA-IR, T2D,
hypertension or CVD in men and women (Table 3).
Anthropometric Associations with VAT
WC, HC, ThC and BMI were positively associated with total
abdominal adipose tissue, VAT and abdominal subcutaneous
adipose tissue in both men and women (Table 4). Following
adjustment for WC, the associations between HC and ThC with
VAT were inversed, such that HC and thigh circumference were
negatively associated with VAT in men and women (Table 5). HC
in men and women as well as ThC in men remained significant
correlates of VAT after further control for age. Although for a
given WC HIV-infected patients with a lower HC or ThC had
increased levels of VAT, the increase was not substantial by
comparison to WC alone. For example, in men, the inclusion of
HC or ThC added just 3% to the variance explained for VAT,
while in women, the inclusion of HC and ThC increased the
Table 1. Patient characteristics.
Men (n=1481) Women* (n=841)
Demographics
Age, y 45.967.3 43.166.9
Smoke ($1 cigs/day), % 47.1 49.0
Alcohol Consumption, % 49.3 39.8
Physical Activity, % 36.1 27.8
Anthropometrics
BMI, kg/m2 24.163.8 22.564.0
Waist circumference, cm 88.0610.1 82.7610.3
Thigh circumference cm 47.864.3 44.864.9
Hip circumference, cm 90.066.3 88.867.3








Total fat 10.666.4 13.666.9
Arm fat 1.761.3 2.461.6
Arm lean 7.661.4 4.861.2
Leg fat 2.261.8 3.362.4
Leg lean 17.962.7 12.761.9
Cardiovascular Risk Factors
Total Cholesterol, mmol/L 4.861.2 4.961.3
Triglycerides, mmol/L 2.562.0 1.861.2
HDL, mmol/L 1.160.4 1.360.4
LDL, mmol/L 2.961.0 3.061.0
HOMA-IR 4.665.8 3.964.0
Fasting Glucose, mmol/L 5.461.2 5.161.1
Fasting Insulin, mU/mL 18.3618.6 16.5614.3
Outcomes
HOMA-IR$3, % 44.8 37.9
Type 2 diabetes, % 9.2 5.7
Hypertension, % 43.1 23.6
Cardiovascular disease, % 5.1 1.6
HIV





Data presented as percent, mean 6 SD, or median (interquartile range).
*With the exception of LDL and CD4, differences between sexes were
significant (p#0.05).
doi:10.1371/journal.pone.0062538.t001
Table 2. Univariate associations between WC, HC, thigh
circumference, BMI and WHR with HOMA-IR, T2D,
hypertension and CVD.
Men Women
OR 95% CI OR 95% CI
HOMA-IR$3
WC 1.06* 1.05–1.08 1.06* 1.04–1.08
HC 1.06* 1.03–1.08 1.04* 1.01–1.06
ThC 1.04* 1.02–1.07 1.03* 1.00–1.07
BMI 1.16* 1.12–1.21 1.17* 1.12–1.23
WHR 1.06* 1.05–1.08 1.04* 1.03–1.07
T2D
WC 1.03* 1.02–1.05 1.02 0.99–1.05
HC 1.02 0.98–1.05 0.99 0.95–1.04
ThC 0.99 0.95–1.04 0.92 0.88–1.01
BMI 1.07* 1.02–1.12 1.06 0.99–1.13
WHR 1.08* 1.05–1.11 1.05* 1.01–1.09
Hypertension
WC 1.04* 1.03–1.05 1.04* 1.02–1.06
HC 1.04* 1.02–1.06 1.04* 1.01–1.06
ThC 1.01 0.99–1.04 1.03 0.99–1.06
BMI 1.08* 1.05–1.12 1.11* 1.07–1.15
WHR 1.06* 1.05–1.08 1.04* 1.02–1.07
CVD
WC 1.04* 1.02–1.06 1.05* 1.01–1.10
HC 1.03 1.00–1.07 1.06* 1.01–1.12
ThC 1.00 0.95–1.05 1.00 0.89–1.12
BMI 1.07* 1.02–1.13 1.11* 1.01–1.22
WHR 1.08* 1.05–1.11 1.04 0.96–1.11
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; HC, hip
circumference; ThC, thigh circumference; WC, waist circumference; T2D, type 2
diabetes; WHR, waist-to-hip-ratio (per 0.01 increase).
*p#0.05.
doi:10.1371/journal.pone.0062538.t002
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Table 3. Multivariate associations between WC, HC, thigh circumference and BMI with HOMA-IR, T2D, hypertension and CVD.
Men Women
WC HC WC HC
HOMA-IR
Model 1 1.14* (1.11–1.17) 0.90* (0.86–0.94) 1.11* (1.08–1.15) 0.93* (0.89–0.96)
Model 2 1.13* (1.10–1.16) 0.91* (0.87–0.95) 1.11* (1.08–1.14) 0.93* (0.89–0.97)
T2D
Model 1 1.09* (1.05–1.13) 0.90* (0.85–0.96) 1.07* (1.02–1.12) 0.92* (0.85–0.98)
Model 2 1.07* (1.03–1.11) 0.91* (0.86–0.96) 1.05* (1.01–1.10) 0.91* (0.84–0.98)
Hypertension
Model 1 1.06* (1.04–1.09) 0.96* (0.93–0.99) 1.05* (1.02–1.07) 0.99 (0.95–1.02)
Model 2 1.05* (1.03–1.07) 0.96* (0.93–0.99) 1.04* (1.01–1.07) 0.98 (0.95–1.02)
CVD
Model 1 1.08* (1.04–1.12) 0.93* (0.87–0.99) 1.03 (0.96–1.11) 1.03 (0.94–1.13)
Model 2 1.06* (1.02–1.11) 0.94* (0.88–0.99) 1.03 (0.95–1.11) 1.02 (0.92–1.14)
WC ThC WC ThC
HOMA-IR
Model 3 1.10* (1.08–1.12) 0.93* (0.89–0.97) 1.08* (1.06–1.11) 0.94* (0.90–0.98)
Model 4 1.08* (1.06–1.11) 0.97 (0.93–1.01) 1.08* (1.06–1.11) 0.94* (0.90–0.98)
T2D
Model 3 1.05* (1.03–1.08) 0.92* (0.87–0.98) 1.05* (1,02–1.08) 0.88* (0.83–0.95)
Model 4 1.03* (1.00–1.05) 0.96 (0.90–1.02) 1.03 (0.99–1.06) 0.91* (0.85–0.98)
Hypertension
Model 3 1.05* (1.04–1.07) 0.95* (0.92–0.97) 1.04* (1.02–1.06) 0.98 (0.95–1.02)
Model 4 1.04* (1.02–1.05) 0.97* (0.93–1.00) 1.03* (1.01–1.05) 1.01 (0.97–1.05)
CVD
Model 3 1.06* (1.04–1.09) 0.92* (0.86–0.98) 1.07* (1.02–1.12) 0.94 (0.84–1.05)
Model 4 1.04* (1.01–1.07) 0.96 (0.90–1.03) 1.05 (0.99–1.10) 0.97 (0.86–1.10)
WC BMI WC BMI
HOMA-IR
Model 5 1.07* (1.03–1.10) 1.03 (0.95–1.12) 1.04* (1.01–1.08) 1.07 (0.97–1.17)
Model 6 1.04* (1.00–1.07) 1.12* (1.02–1.22) 1.05* (1.01–1.08) 1.07 (0.97–1.17)
T2D
Model 5 1.05* (1.01–1.10) 0.95 (0.85–1.06) 1.00 (0.95–1.06) 1.05 (0.93–1.20)
Model 6 1.03 (0.98–1.07) 0.98 (0.87–1.10) 0.99 (0.93–1.05) 1.05 (0.92–1.22)
Hypertension
Model 5 1.06* (1.04–1.09) 0.94* (0.89–0.99) 1.01 (0.98–1.04) 1.07* (1.00–1.16)
Model 6 1.04* (1.02–1.07) 0.96 (0.90–1.02) 1.01 (0.98–1.04) 1.08* (1.00–1.16)
CVD
Model 5 1.08* (1.03–1.13) 0.90 (0.79–1.02) 1.05 (0.96–1.15) 0.99 (0.80–1.24)
Model 6 1.05 (1.00–1.10) 0.94 (0.83–1.08) 1.04 (0.94–1.14) 1.01 (0.80–1.27)
Model 1 includes WC and HC as independent variables.
Model 2 includes WC, HC and covariates (age, physical activity, smoking) as independent variables.
Model 3 includes WC and thigh circumference (ThC) as independent variables.
Model 4 includes WC, ThC and covariates (age, physical activity, smoking) as independent variables.
Model 5 includes WC and BMI as independent variables.
Model 6 includes WC, BMI and covariates (age, physical activity, smoking) as independent variables.
Data presented as OR (95% CI).
Abbreviations: BMI, body mass index; CVD, cardiovascular disease; HC, hip circumference; ThC, thigh circumference; WC, waist circumference; T2D, type 2 diabetes.
*p#0.05.
doi:10.1371/journal.pone.0062538.t003
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variance explained for VAT by 1–2%. In general, similar
observations were observed for total abdominal adipose tissue
and abdominal subcutaneous adipose tissue (Table 5).
Discussion
The primary finding of this study was that the identification of
HIV-infected patients at increased risk by WC alone is substan-
tially improved by the addition of HC. These observations
reinforce the recommendation that WC and HC should be used in
combination to identify higher-risk HIV-infected adults, in
particular men, and that identification of HIV-infected adults
with elevated health risk may be underestimated when WC is used
alone. Our observations also suggest that the ability of WC and
HC combined to predict VAT might not be the conduit by which
these anthropometric measures combined identify those at
increased risk of cardiometabolic risk and morbidity.
To our knowledge no prior study has determined whether HC
adds to the health risk identified by WC alone in HIV-infected
patients. Our finding is consistent with prior studies in non-HIV
individuals investigating the associations of WC and HC with
morbidity, which have also demonstrated a protective effect of an
increased HC for a given WC and/or BMI [2,4,7,13,21]. For
example, Sakai et al. [21] reported that upon control for WC in
men and women, the odds ratios for hypertension and T2D
ranged from 0.88 to 0.94 per 1 cm increase in HC, which are of
similar magnitude to those reported here.
The importance of our primary finding can be appreciated by
comparing the health risk of a 1 cm difference in both WC and
HC with a 1 cm difference in WC alone. If an HIV-infected
Table 4. Univariate associations between WC, HC, thigh
circumference, BMI and WHR with total abdominal adipose
tissue, VAT and abdominal subcutaneous adipose tissue.
Men Women
b r2 b r2
TAAT
WC 12.73 0.70 11.59 0.50
HC 17.54 0.51 14.05 0.37
ThC 16.61 0.22 14.16 0.17
BMI 31.93 0.60 28.20 0.44
WHR 14.96 0.41 10.50 0.21
VAT
WC 5.44 0.38 3.97 0.20
HC 6.54 0.23 3.37 0.07
ThC 5.64 0.08 2.95 0.03
BMI 12.84 0.30 8.23 0.12
WHR 7.33 0.30 4.97 0.16
ASAT
WC 7.30 0.59 7.62 0.50
HC 11.00 0.52 10.68 0.50
ThC 11.00 0.24 11.21 0.24
BMI 19.08 0.56 19.97 0.52
WHR 7.63 0.28 5.53 0.14
Abbreviations: ASAT, abdominal subcutaneous adipose tissue; BMI, body mass
index; HC, hip circumference; ThC, thigh circumference; TAAT, total abdominal
adipose tissue; VAT, visceral adipose tissue; WC, waist circumference; WHR,
waist-to-hip ratio.
All associations were significant (p,0.001).
doi:10.1371/journal.pone.0062538.t004
Table 5. Multivariate associations between WC, HC, thigh
circumference and BMI with total abdominal adipose tissue,
VAT and abdominal subcutaneous adipose tissue.
Men Women
b r2 b r2
TAAT
Model 1
WC 11.67* 0.70 9.40* 0.51
HC 2.04* 4.02*
Model 2
WC 12.85* 0.69 10.73* 0.51
ThC 20.43 3.65*
Model 3
WC 10.12* 0.70 8.10* 0.52
BMI 7.88* 10.57*
Model 4
WHR 14.8* 0.41 10.3* 0.21
VAT
Model 1
WC 6.00* 0.41 4.90* 0.22
HC 21.70* 21.99*
Model 2
WC 5.44* 0.41 4.02* 0.21
ThC 21.35* 20.82
Model 3
WC 4.88* 0.41 4.21* 0.21
BMI 0.73 21.17
Model 4
WHR 6.78* 0.32 4.80* 0.18
ASAT
Model 1
WC 5.67* 0.63 4.49* 0.57
HC 3.75* 6.01*
Model 2
WC 7.41* 0.61 6.71* 0.53
ThC 0.92* 4.48*
Model 3
WC 5.24* 0.63 3.89* 0.56
BMI 7.16* 11.74*
Model 4
WHR 8.01* 0.29 5.56* 0.14
Model 1 includes WC, HC and age as independent variables.
Model 2 includes WC, thigh circumference and age as independent variables.
Model 3 includes WC, BMI and age as independent variables.
Model 4 includes WHR and age as independent variables.
Abbreviations: ASAT, abdominal subcutaneous adipose tissue; BMI, body mass
index; HC, hip circumference; ThC, thigh circumference; TAAT, total abdominal
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patient has a 1 cm greater WC and a 1 cm lower HC compared to
another HIV-infected patient, the risk of HOMA-IR and T2D
using WC and HC will increase 14–22% in men and women,
while the risk is just 3–8% using WC alone. Similarly in an HIV-
infected man, a 1 cm greater WC combined with a 1 cm lower
HC, compared to another HIV-infected man, will increase the risk
of hypertension and CVD 9–12% using WC and HC whereas the
use of WC alone is associated with an increased risk approximat-
ing 4%. Given that lower body subcutaneous adipose tissue is a
common site for loss of adipose tissue in HIV-infected adults
[22,23,24], a strong argument exists for the routine acquisition of
WC and HC in clinical settings.
Our findings that derive from the use of simple anthropometric
tools that are readily available to the practitioner are consistent
with studies in HIV-infected patients wherein sophisticated
radiographic methods were used [25,26,27,28]. For example,
Mynarcik et al. [26] previously showed that after control for trunk
adipose tissue, the loss of peripheral adipose tissue measured by
DXA was strongly associated with insulin resistance. Similarly,
Lake et al. [28] reported that leg subcutaneous adipose tissue
measured by magnetic resonance imaging was negatively associ-
ated with CVD risk following control for VAT.
The mechanism that would explain why HC is negatively
associated with increased cardiometabolic risk and morbidity
following control for WC is unclear. An emerging hypothesis is
that dysfunctional, insulin-resistant subcutaneous adipocytes are
unable to entrap extra energy which may result in a spillover into
ectopic tissues, such as the liver, the heart, the skeletal muscle or
VAT [17]. Therefore, lower-body subcutaneous adipose tissue
may play a protective role by acting as a buffer through storage of
excess lipids thus limiting lipid deposition in ectopic tissues.
Treatment with ART has been shown to cause mitochondrial
dysfunction and enhanced lipolysis as well as impaired glucose
uptake in subcutaneous adipose tissue, which may lead to
adipocyte dysfunction or apoptosis [19,29]. Thus lower HC values
in HIV-infected patients may indicate the presence of dysfunc-
tional lower-body adipocytes which are unable to store excess
energy resulting in a decrease in adipose tissue mass. Presumably
this would lead to a greater accumulation of lipid in ectopic tissues
including VAT.
Consistent with this hypothesis we observed that HC was
negatively associated with VAT after control for WC, a finding
consistent with previous observations in non-HIV adults [18].
However, the magnitude of the increase in VAT predicted by the
combination of WC and HC compared to WC alone was subtle
averaging 3% (,4 cm3) in men and 2% (,2 cm3) in women. It is
unlikely that differences in VAT estimation of this magnitude
would mediate the incremental increase in health risk identified by
HC. It is possible that HC in combination with WC identifies
ectopic fat deposition in tissues other than VAT including liver
and/or epicardial tissues both of which are associated with
increased health risk [30]. Although the mechanisms that explain
why health risk is substantially elevated by the combination of WC
and HC compared to WC alone remain to be determined, it is
noted that numerous studies report an inverse association between
lower-body adipose tissue and morbidity after control for
abdominal adiposity in non-HIV adults [2,6,7,10,13,21].
Although ThC was negatively associated with all our outcomes
after control for WC independent of gender, unlike HC the
associations did not persist after control for covariates. This was a
surprising result because we had no reason to believe that the
anthropometric variables represent adipose tissue depots that vary
metabolically. A threshold value for ThC that delineates increased
morbidity risk in HIV-infected persons is unknown, however, the
ThC values for our sample (,46 cm) is well below the ThC
threshold for CVD (,60 cm) reported for non-HIV men and
women [12]. The recent observation that lipoatrophy as measured
by leg SAT is negatively associated with CVD risk independent of
VAT in HIV-infected adults [28] suggests that further research is
warranted to determine the optimal use of ThC in clinical
practice.
Our study is cross-sectional in design and causality cannot be
assumed. Further, whether simultaneous changes in WC and/or
HC over time identify increased risk of morbidity cannot be
inferred. The subjects studied were referred to the HIV clinic with
specific metabolic disorders and thus generalizability of our
findings across the HIV population is unclear. The relatively
small sample size precludes the derivation of algorithms and/or
cut-point values for HC in combination with WC that would be
required to identify those at increased health risk.
Our findings demonstrate that the identification of HIV-
infected individuals at increased health risk by WC alone is
substantially improved by the addition of HC. Further study with
large sample sizes is required to develop valid algorithms or cut-
point values that could ultimately be incorporated into routine
clinical practice to help identify high-risk HIV patients.
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